首页> Investigational new drugs> AN-7, a butyric acid prodrug, sensitizes cutaneous T-cell lymphoma cell lines to doxorubicin via inhibition of DNA double strand breaks repair.

AN-7, a butyric acid prodrug, sensitizes cutaneous T-cell lymphoma cell lines to doxorubicin via inhibition of DNA double strand breaks repair.

导出原文传递

翻译打印收藏纠错

第一作者： Lilach,Moyal

第一单位： Laboratory for Molecular Dermatology, Felsenstein Medical Research Center, Petach Tikva and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. lilachm@post.tau.ac.il.;Department of Dermatology, Rabin Medical Center, Petach Tikva, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. lilachm@post.tau.ac.il.

作者： Lilach,Moyal ^[1] ; Neta,Goldfeiz ^[2] ; Batia,Gorovitz ^[2] ; Ada,Rephaeli ^[3] ; Efrat,Tal ^[4] ; Nataly,Tarasenko ^[3] ; Abraham,Nudelman ^[5] ; Yael,Ziv ^[4] ; Emmilia,Hodak ^[2]

作者单位： Laboratory for Molecular Dermatology, Felsenstein Medical Research Center, Petach Tikva and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. lilachm@post.tau.ac.il.;Department of Dermatology, Rabin Medical Center, Petach Tikva, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. lilachm@post.tau.ac.il. ^[1] Laboratory for Molecular Dermatology, Felsenstein Medical Research Center, Petach Tikva and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.;Department of Dermatology, Rabin Medical Center, Petach Tikva, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. ^[2] Laboratory for Pharmacology and Experimental Oncology, Felsenstein Medical Research Center, Petach Tikva, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. ^[3] The David and Inez Myers Laboratory for Cancer Research, Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. ^[4] Division of Medicinal Chemistry, Department of Chemistry, Bar Ilan University, Ramat Gan, Israel. ^[5]

关键词 AN-7 Cutaneous T-cell lymphoma (CTCL)Doxorubicin Histone deacetylase inhibitor (HDACI)Mycosis fungoides (MF)Sezary syndrome (SS)